Third Time Lucky As Japan Finally Approves Shionogi’s Oral COVID Antiviral

Simpler Dosing To Help Xocova?

Shionogi’s once-daily oral COVID-19 antiviral finally gets Japan approval after being considered for the third time by an expert panel, paving the way for public availability of the country’s first such home-grown option in early December.

The Japanese government finally approved Xocova after third discussion
Japan finally gives stamp of approval to Xocova • Source: Shutterstock

Shionogi & Co. Ltd.’s oral antiviral for COVID-19, Xocova (ensitrelvir), has been approved in Japan on its third attempt and will become the third such drug available in the country, although the first to have been developed by a domestic pharma firm.

The 3CL protease inhibitor was granted authorization by the Ministry of Health, Labour and Welfare under an urgent approval system...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Japan

More from Focus On Asia